Unity Biotech posts better than expected Q2 results, expects to share clinical trial results early 2019

SAN FRANCISCO, Aug. 09, 2018-- UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to extend healthspan by slowing, halting.

https://www.nasdaq.com/press-release/unity-biotechnology-inc-reports-second-quarter-2018-financial-results-20180809-01101

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website, NutritionTheory.org

View all posts by Robert Zinn →